Advertisement

Topics

Search Results for "Alzheimers Disease Update"

15:22 EST 4th December 2016 | BioPortfolio

Matching Channels

Vascular Dementia

Vascular Dementia accounts for 25% of all dementias (the second most commen cause after Alzheimers. It is the cumulative effects of many small strokes - patients often have evidence of vascular path...

Eye disease

Gaucher's disease

Gaucher's (go-SHAYZ) disease occurs when certain harmful fatty substances accumulate to excessive levels in your liver, spleen, lungs, bone marrow and, less commonly, brain. This accumulation of...

Mayaro disease

MarchiafavaBignami Disease

Matching News

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune&...

Another “Almost” against Alzheimers: Lundbeck’s Phase III Flop

Alzheimer’s Disease is the most common form of dementia, affecting 15M people across the world. With the most recent failure of idalopirdine, a cure will remain elusive for now. As Derek Lowe ob...

AC Immune sets IPO value for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune&...

Different brain atrophy patterns may explain variability in Alzheimers disease symptoms

(Massachusetts General Hospital) Mathematical modeling of the brain scans of patients with Alzheimer's disease and others at risk for the devastating neurodegenerative disorder has identified specific...

BRIEF-BioMarin announces update to Brineura program

* BioMarin announces update to Brineura (cerliponase alfa) program for treatment of CLN2 disease, a form of batten disease

FRANCE-HEALTH-DISEASE-ALZHEIMERS

TO GO WITH AFP STORY BY MARIETTE LE ROUX - A woman, suffering from Alzheimer's desease, holds the hand of a relative on March 18, 2011 in a retirement house in Angervilliers, eastern France. AFP ...

BRIEF-Redhill Biopharma provides progress update on RHB-104 Phase III crohn's disease program

* Redhill Biopharma provides progress update on RHB104 Phase III crohn's disease program and introduces option for early stop for success in Q2/2017

IntelGenx starts phase 1 clinical trial of montelukast

IntelGenx has started a phase 1 clinical trial of montelukast, a drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers...

Matching PubMed Articles

Some aspects of the immune system in the pathogenesis of Alzehimers disease.

Alzheimers disease is a severe neurodegenerative disorder and the most common cause of dementia in the population above 60 years of age. Beta-amyloid accumulation and neurofibrillary tangles formation...

Trends in urological stone disease: a 5-year update of Hospital Episode statistics.

To provide a 5-year follow-on update on the changes in prevalence and treatment of upper urinary tract stone disease in the UK.

An update on ocular allergy.

The update reviews prevalence, classification, cause, and treatment options for allergic eye disease.

Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease.

Some Alzheimer's disease (AD) patients die without ever developing cognitively impaired basic activities of daily living (basic ADL), which may reflect slower disease progression or better compensator...

Care of Women During Menopause.

We would like to introduce a new section in the Journal of Women's Health, the Clinical Update. Important studies are continually published in both this Journal and other medical publications. However...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement